Marleen van den Horst

T: +31 70 376 06 21
E: marleen.vandenhorst@barentskrans.nl
View Marleen van den Horst on LinkedIn

Head of the IP & Technology Practice Group Marleen van den Horst (PhD) has extensive experience in complex, multi-jurisdictional IP litigation.  She has specialised in patent litigation in all fields of technology, including mechanical engineering, electronics, chemistry and life sciences. From ship hatches, electronic braille cells, glass house lighting, electronic queue systems, machines for cleaning sportsfields to medical devices and medicines. Marleen is internationally renowned for her work in the life sciences. She has frequently acted as lead counsel in high profile pharmaceutical patent/SPC and regulatory proceedings regarding molecules such as cimetidine, ciclosporin, omeprazole, alendronate, lansoprazole, fluvastatin, escitalopram, clopidogrel, esomeprazole, valsartan and modafinil. In addition, she is involved in (the preparation of) patent litigation concerning monoclonal antibodies, the next generation of medicinal products that will be the subject of intensive patent litigation. Together with her team, she assists clients in negotiating and drafting licences, technology transfer and distribution agreements.

Selected directory listings

Extremely personable’ regulatory and patents expert Marleen van den Horst, who has ‘a depth of experience few can rival‘, is awarded the title of ‘Leading Individual’ in Healthcare and Life sciences.  – Legal 500, 2018

Clients praise her “outstanding knowledge, good commercial awareness and customer focus.” – Chambers Global & Europe, 2018

Received the Client Choice award in ‘Healthcare & Life Sciences’ – Client Choice, 2o18

Marleen van den Horst is praised for her “good understanding of biochemical technology.” – Chambers Global, 2017

‘First-class’ department head Marleen van den Horst is widely recommended. – Legal 500, 2017

Marleen van den Horst is described as “inventive, proactive, skilled,” as well as “highly personable and technically very able”. Clients say that Marleen van den Horst is “very energetic, very engaged, never gives up and always tries to find a way.” – Chambers Europe, 2016

Efficient, organised and practical, she is heavily involved in the sector. She always makes herself readily available to answer your questions and will address issues in a manner that enhances your case’s strengthsIAM Patent 1000, 2016

BarentsKrans’ team is headed up by the ‘formidable’ and ‘tenacious’ Marleen van den Horst. The team is “praised for its ‘practical’ and ‘commercial’ advice”Legal 500, 2016

Professional activities

Member of the Standing Committee on IP of the Netherlands Bar Association
Member of the International Board of Women’s World Banking NY (a microfinance NGO)
Member of the Board of the NeoKidney Foundation

News and publications

Pharma update: injunction against generic combination of ezetimibe and simvastatin denied

In the interim relief decision of 11 June 2018 (ECLI:NL:RBDHA:2018:6802) in the matter Merck Sharp & Dohme Corp. / Teva Nederland B.V, Pharmachemie B.V. and Centrafarm B.V. the Provisions Judge of the District Court of The Hague rejected the claim of Merck Sharp & Dohme Corp. for an injunction against the distribution of the generic combination
Read more ›
More from this specialist